The work reported here shows that AXT107, a 20-mer peptide that inhibits VEGF signaling and activates Tie2 though endogenously released Ang2 to help resolve underlying inflammation, could be used to treat DME, DR, RVO, AMD, uveitis, DED, and other ocular diseases that are inadequately treated with the current standard of care therapies. The gene discussed is ANGPT2; the disease is age-related macular degeneration.